Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Caroline Robert,Georgina V. Long,Benjamin Brady,Caroline Dutriaux,Anna Maria Di Giacomo,Laurent Mortier,Piotr Rutkowski,Jessica C. Hassel,Catriona M. McNeil,Ewa Kalinka,Celeste Lebbe,Julie Charles,Micaela Hernberg,Kerry J. Savage,Vanna Chiarion Sileni,Catalin Mihalcioiu,Cornelia Mauch,Ana Arance,Francesco Cognetti,Lars Ny,Henrik Schmidt,Dirk Schadendorf,Helen Gogas,Jesus Zoco,Sandra Re,Paolo A. Ascierto,Victoria Atkinson

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

2020

PURPOSEThe CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented he...

Keywords:

advanced melanoma
Wild type
Internal medicine
in patient
Oncology
Nivolumab
MEDLINE
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations